103 related articles for article (PubMed ID: 8137342)
1. Pharmacokinetics and metabolism of anthracyclines.
Robert J; Gianni L
Cancer Surv; 1993; 17():219-52. PubMed ID: 8137342
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetics of new anthracyclines].
Robert J
Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
[TBL] [Abstract][Full Text] [Related]
3. Dose optimization of anthracyclines.
de Valeriola D
Anticancer Res; 1994; 14(6A):2307-13. PubMed ID: 7825964
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetics and metabolism of anthracyclines in man].
Robert J
Pathol Biol (Paris); 1987 Jan; 35(1):27-30. PubMed ID: 3550609
[TBL] [Abstract][Full Text] [Related]
5. Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.
Hurteloup P; Ganzina F
Drugs Exp Clin Res; 1986; 12(1-3):233-46. PubMed ID: 3525075
[TBL] [Abstract][Full Text] [Related]
6. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
Hong RL; Tseng YL
Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.
Mross K; Niemann B; Massing U; Drevs J; Unger C; Bhamra R; Swenson CE
Cancer Chemother Pharmacol; 2004 Dec; 54(6):514-24. PubMed ID: 15322827
[TBL] [Abstract][Full Text] [Related]
9. Idarubicin: a brief overview on pharmacology and clinical use.
Borchmann P; Hübel K; Schnell R; Engert A
Int J Clin Pharmacol Ther; 1997 Feb; 35(2):80-3. PubMed ID: 9147715
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease.
Morgan DJ; Hill JS; Clarke K; Stylli SS; Park SJ; Cebon J; Basser RL; Kaye AH; Geldard H; Maher DW; Green MD
Cancer Chemother Pharmacol; 1997; 40(3):202-8. PubMed ID: 9219502
[TBL] [Abstract][Full Text] [Related]
11. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
[TBL] [Abstract][Full Text] [Related]
12. Properties of antitumor anthracyclines and new developments in their application: Cain memorial award lecture.
Arcamone F
Cancer Res; 1985 Dec; 45(12 Pt 1):5995-9. PubMed ID: 3864526
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks.
Alberts SR; Erlichman C; Reid JM; Sloan JA; Ames MM; Richardson RL; Goldberg RM
Clin Cancer Res; 1998 Sep; 4(9):2111-7. PubMed ID: 9748127
[TBL] [Abstract][Full Text] [Related]
14. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
Danesi R; Fogli S; Gennari A; Conte P; Del Tacca M
Clin Pharmacokinet; 2002; 41(6):431-44. PubMed ID: 12074691
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
Tamura K
Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
Catimel G; Spielmann M; Dieras V; Kayitalire L; Pouillart P; Guastalla JP; Soler-Michel P; Graffand N; Garet F; Dumortier A; Pellae-Cosset B; Chazard M
Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
[TBL] [Abstract][Full Text] [Related]
19. Role of anthracyclines in the era of targeted therapy.
Cortés-Funes H; Coronado C
Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804
[TBL] [Abstract][Full Text] [Related]
20. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
